Verily announced a $300 million investment round to accelerate its precision health AI strategy, marking a significant step in the company’s evolution as it scales its platform for research and care applications. The funding round was led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors. As part of the transaction, Alphabet will remain a significant minority investor but will no longer hold a controlling stake in the company.
Alongside the investment, Verily has transitioned its legal structure from an LLC to a corporation and will now operate as Verily Health Inc. The company plans to use the new capital to expand its AI-native precision health platform, enabling customers to better harmonize healthcare data, generate insights, and deploy actionable intelligence across clinical and research workflows.
Verily has also been building commercial momentum through a series of partnerships. These include a collaboration with Samsung’s Galaxy Watch to support biomarker development and clinical research, as well as a strategic partnership with Salesforce to integrate the Verily Pre Platform with Agentforce Health. The company is also working with UCHealth, the University of Colorado Anschutz, and RefinedScience to apply its platform in AI-powered research and care transformation.
Originally incubated within Google X, Verily has spent the past decade developing technology at the intersection of data science, healthcare, and artificial intelligence. The company focuses on transforming multimodal health data into predictive, personalized insights to improve outcomes and reduce healthcare costs.
KEY QUOTES:
“Today is an important step in our mission to bring the promise of precision health to everyone. From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare – one that is as precise as it is personal. Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare.”
Stephen Gillett, Chairman And CEO Of Verily
“Series X Capital was established in collaboration with Google’s X, The Moonshot Factory to scale moonshot technologies into consequential, world-changing companies. We are extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health.”
Gideon Yu, Founder And Managing Partner Of Series X Capital
“At Alphabet, we applaud Verily’s tenacity in using technology to address longstanding challenges in the healthcare industry. Bringing in new investors, alongside Alphabet’s ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform.”
Ruth Porat, President And Chief Investment Officer Of Alphabet And Google
“Partnering with Verily to bring a shared data framework to healthcare data, making it AI-ready, creates a generational opportunity for UCHealth and for medicine. This collaboration helps unlock the long-promised potential of personalized care, benefiting our patients and, ultimately, all patients. It will save lives, and we’re eager to get started.”
Richard Zane, MD, UCHealth Chief Medical And Innovation Officer
